A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Biofilms are associated with persistence of Staphylococcus aureus infections and therapeutic failures. Our aim was to set up a pharmacodynamic model comparing antibiotic activities against biofilms and examining in parallel their effects on viability and biofilm mass. Biofilms of S. aureus ATCC 25923 (methicillin-sensitive S. aureus [MSSA]) or ATCC 33591 (methicillin-resistant S. aureus [MRSA]) were obtained by culture in 96-well plates for 6 h/24 h. Antibiotic activities were assessed after 24/48 h of exposure to concentrations ranging from 0.5 to 512 times the MIC. Biofilm mass and bacterial viability were quantified using crystal violet and the redox indicator resazurin. Biofilms stained with Live/Dead probes were observed by using confocal microscopy. Concentration-effect curves fitted sigmoidal regressions, with a 50% reduction toward both matrix and viability obtained at sub-MIC or low multiples of MICs against young biofilms for all antibiotics tested. Against mature biofilms, maximal efficacies and potencies were reduced, with none of the antibiotics being able to completely destroy the matrix. Delafloxacin and daptomycin were the most potent, reducing viability by more than 50% at clinically achievable concentrations against both strains, as well as reducing biofilm depth, as observed in confocal microscopy. Rifampin, tigecycline, and moxifloxacin were effective against mature MRSA biofilms, while oxacillin demonstrated activity against MSSA. Fusidic acid, vancomycin, and linezolid were less potent overall. Antibiotic activity depends on biofilm maturity and bacterial strain. The pharmacodynamic model developed allows ranking of antibiotics with respect to efficacy and potency at clinically achievable concentrations and highlights the potential utility of daptomycin and delafloxacin for the treatment of biofilm-related infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this assay cannot assess the viability of cells remaining within the biofilm structure (Bauer et al., 2013).”
From Manuka-type honeys can eradicate biofilms produced by Staphylococcus aureus strains with different biofilm-forming abilities (2014) · cites this paper as Bauer et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of biofilm resistance to antimicrobial agents
Mah, T.-F. C., & O'Toole, G. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(00)01913-2 · Cited by 3,921
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Key Role of Teichoic Acid Net Charge in Staphylococcus aureus Colonization of Artificial Surfaces
Gross, M., Cramton, S. E., Götz, F., & Peschel, A. (2001) · Infection and Immunity · doi:10.1128/iai.69.5.3423-3426.2001 · Cited by 554
Innate and Induced Resistance Mechanisms of Bacterial Biofilms
Anderson, G. G., & O'Toole, G. A. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-75418-3_5 · Cited by 438 · cited 1×
“Thus, the apparent resistance to antibiotics of bacteria growing in biofilms is probably multifactorial, with a combination of mechanisms that are both innate (decreases in antibiotic access, oxygen, and nutrient availability and lower metabolic activity) or induced by antibiotic exposure (like stress response and/or…”
BackgroundKaplan, J. B., Izano, E. A., Gopal, P., Karwacki, M. T., Kim, S., Bose, J. L., Bayles, K. W., & Horswill, A. R. (2012) · mBio · doi:10.1128/mbio.00198-12 · Cited by 287
Daddi Oubekka, S., Briandet, R., Fontaine-Aupart, M.-P., & Steenkeste, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00216-12 · Cited by 130
LaPlante, K. L., & Woodmansee, S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00134-09 · Cited by 110
Segreti, J. A., Crank, C. W., & Finney, M. S. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.347 · Cited by 88
Kirby, A. E., Garner, K., & Levin, B. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06480-11 · Cited by 72
Research works printed but not linked: 56
- 10.4161/viru.2.5.17724 · DOI · Paper page
- 10.1111/j.1462-5822.2009.01323.x · DOI · Paper page
- 10.1371/journal.pone.0031780 · DOI
- 10.2174/092986708786848442 · DOI
- OttoM. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207–228.
- 10.1128/AAC.00350-06 · DOI · Paper page
- 10.1128/AAC.00455-10 · DOI
- 10.1111/j.1574-695X.2010.00701.x · DOI
- 10.1128/AAC.01642-08 · DOI
- 10.1016/j.ijantimicag.2007.11.012 · DOI
- 10.1016/j.ijantimicag.2007.06.029 · DOI
- 10.1590/S0037-86822012000400011 · DOI
- WuWS ChenCC ChuangYC SuBA ChiuYH HsuHJ KoWC TangHJ. 9 May 2012. Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant Staphylococcus aureus. J. Microbiol. Immunol. Infect. [Epub ahead of print.] doi:10.1016/j.jmii.2012.03.009. · DOI
- 10.1016/j.ijantimicag.2008.08.029 · DOI
- 10.1016/j.diagmicrobio.2010.11.018 · DOI
- 10.1016/j.ijantimicag.2008.11.004 · DOI
- 10.1016/j.mimet.2009.04.014 · DOI
- 10.1007/s12223-010-0012-y · DOI
- 10.1002/jobm.201000034 · DOI
- 10.1128/iai.37.1.318-326.1982 · DOI · Paper page
- 10.1128/AEM.02095-09 · DOI · Paper page
- 10.1111/j.1472-765X.2007.02298.x · DOI
- Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing, 22nd informational supplement. CLSI document MS100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
- 10.1016/j.foodres.2005.05.006 · DOI
- 10.1111/j.1574-695X.2012.00961.x · DOI
- AmsdenGW. 2009. Tables of antimicrobial agent pharmacology, p 705–764. In MandellGL BennettJE DolinR (ed), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Elsevier, Philadelphia, PA.
- LawrenceL BenedictM HartJ HawkinsA LiD MedlockM HopkinsS BurakE. 2011. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects, poster A2-045a. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC). American Society for Microbiology, Washington, DC.
- Anonymous. 2005. Zyvox. U.S. full prescribing information. Pharmacia & Upjohn, Division of Pfizer, Inc., New York, NY.
- 10.1007/s002640050116 · DOI
- 10.1016/j.actbio.2009.08.040 · DOI
- 10.1093/jac/44.1.43 · DOI · Paper page
- 10.1128/AAC.01180-12 · DOI
- 10.1016/j.diagmicrobio.2012.05.034 · DOI
- 10.1038/ja.2012.49 · DOI
- 10.1016/j.mimet.2012.01.007 · doi:10.1016/j.mimet.2012.01.007
- 10.5301/ijao.5000061 · DOI
- 10.1007/978-1-59745-468-1_10 · DOI · Paper page
- 10.1016/j.jhin.2005.06.004 · DOI · Paper page
- 10.1128/JB.186.3.722-729.2004 · DOI · Paper page
- 10.1002/jobm.201000221 · DOI · Paper page
- 10.1093/jac/dkr043 · DOI
- 10.5301/ijao.5000027 · DOI · Paper page
- 10.1093/jac/dkq257 · DOI · Paper page
- 10.1128/AAC.50.3.841-851.2006 · DOI · Paper page
- 10.1128/AAC.01201-10 · doi:10.1128/aac.01201-10
- 10.1371/journal.ppat.1002626 · DOI · Paper page
- 10.1080/08927014.2011.604776 · DOI
- 10.1155/2012/976972 · doi:10.1155/2012/976972
- 10.1016/j.micpath.2009.09.011 · doi:10.1016/j.micpath.2009.09.011
- 10.1128/JCM.02280-06 · DOI · Paper page
- 10.2165/00003495-200969100-00005 · DOI
- 10.1016/j.ijantimicag.2010.03.015 · DOI
- 10.1007/s10096-011-1160-y · DOI
- 10.1093/cid/cir805 · DOI
- 10.1128/AEM.71.5.2501-2510.2005 · DOI · Paper page
- 10.1371/journal.pone.0025299 · doi:10.1371/journal.pone.0025299
Cited by
Options and Limitations in Clinical Investigation of Bacterial Biofilms
Magana, M., Sereti, C., Ioannidis, A., Mitchell, C. A., Ball, A. R., Magiorkinis, E., Chatzipanagiotou, S., Hamblin, M. R., Hadjifrangiskou, M., & Tegos, G. P. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-16 · Cited by 242
Lu, J., Turnbull, L., Burke, C. M., Liu, M., Carter, D. A., Schlothauer, R. C., Whitchurch, C. B., & Harry, E. J. (2014) · PeerJ · doi:10.7717/peerj.326 · Cited by 184
Metadata
- Authors
- Bauer, J., Siala, W., Tulkens, P. M., & Van Bambeke, F.
- Affiliations
- Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-06
- Volume
- 57
- Issue
- 6
- Pages
- 2726-2737
- ISSN
- 0066-4804
- 1098-6596
- Cited by
- 130
- References
- 9
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.